Close Menu

NanoString

NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market Tuesday that several US clinical laboratories will adopt the company's breast cancer assay starting in the first quarter of 2014.

Transgenomic has appointed Stephen Miller as senior vice president and general manager of its patient testing business unit.

NanoString Technologies last week reported a 39 percent increase in third quarter revenues while company executives offered an overview of the Seattle-based company's opportunities in the molecular diagnostics and life science research markets.

NEW YORK (GenomeWeb News) – NanoString Technologies reported after the close of the market Tuesday that its third quarter revenues climbed 39 percent as the firm reported growth for both its instruments and consumables.

NEW YORK (GenomeWeb News) – Fluidigm and NanoString Technologies have settled lawsuits filed by Fluidigm that accused NanoString of false advertising, unfair competition, and unlawful trade practice, the companies announced after the close of the market on Tuesday.

NEW YORK (GenomeWeb News) – Shares of omics tools and molecular diagnostics firms bounced back in September, lifted by the broader market, after a sluggish August.

After receiving 510(k) clearance this week from the US Food and Drug Administration for its Prosigna Breast Cancer Prognostic Gene Signature Assay, NanoString will take the next few months to make agency-requested changes to the test report and engage in discussions with potentia

NanoString Technologies is no newcomer to the single-cell genomics market. The firm last year launched a single-cell gene expression assay for use on its nCounter Analysis System.

NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market Monday that the US Food and Drug Administration has granted 510(k) clearance of the firm's Prosigna Breast Cancer Prognostic Gene Signature Assay.

NEW YORK (GenomeWeb News) – NanoString Technologies and BD segment BD Biosciences today announced a collaboration to develop a single-cell isolation and analysis workflow.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.